Early investigational tubulin inhibitors as novel cancer therapeutics

研究成果: 雜誌貢獻回顧型文獻同行評審

19 引文 斯高帕斯(Scopus)


ABSTRACT: Introduction: Microtubules represent one of the most logical and strategic molecular targets amongst the current targets for chemotherapy, alongside DNA. In the past decade, tubulin inhibitors as cancer therapeutics have been an area of focus due to the improved understanding and biological relevance of microtubules in cellular functions. Fueled by the objective of developing novel chemotherapeutics and with the aim of establishing the benefits of tubulin inhibition, several clinical trials have been conducted with others ongoing. Area covered: At present, the antitubulin development pipeline contains an armful of agents under clinical investigation. This review focuses on novel tubulin inhibitors as cancer therapeutics. The article covers the agents which have completed the phase II studies along with the agents demonstrating promising results in phase I studies. Expert opinion: Countless clinical trials evaluating the efficacy, safety and pharmacokinetics of novel tubulin inhibitors highlights the scientific efforts being paid to establish their candidature as cancer therapeutics. Colchicine binding site inhibitors as vascular disrupting agents (VDAs) and new taxanes appear to be the most likely agents for future clinical interest. Numerous agents have demonstrated clinical benefits in terms of efficacy and survival in phase I and II studies. However conclusive benefits can only be ascertained on the basis of phase III studies.
頁(從 - 到)917-936
期刊Expert Opinion on Investigational Drugs
出版狀態已發佈 - 八月 2 2016


  • colchicine
  • efficacy
  • microtubules
  • objective response
  • overall survival
  • progression free survival
  • solid tumors
  • taxanes
  • Tubulin inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

指紋 深入研究「Early investigational tubulin inhibitors as novel cancer therapeutics」主題。共同形成了獨特的指紋。